株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

合成生物学:世界市場

Synthetic Biology: Global Markets

発行 BCC Research 商品コード 224398
出版日 ページ情報 英文 266 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
合成生物学:世界市場 Synthetic Biology: Global Markets
出版日: 2017年01月27日 ページ情報: 英文 266 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の合成生物学市場は、2016年の39億米ドルから、2021年までに114億米ドルまで拡大すると見られています。市場は、2016年〜2021年のCAGR (複合年間成長率) で、24.0%の成長が予測されています。

当レポートでは、世界の合成生物学市場について調査分析し、主要製品、実現技術、対応技術に焦点を当てて、5ヶ年予測、戦略的提携、産業構造、競合情勢、特許、市場促進要因など、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 合成生物学技術
  • 合成生物学とは
  • 合成生物学の開発段階
  • 合成生物学市場の成長促進要因
  • 世界の合成生物学関連製品市場
  • 製品・技術のライフサイクル状況
  • 合成生物学産業

第4章 合成生物学技術

  • イントロダクション
  • バイオ燃料技術
  • 二酸化炭素原料

第5章 合成生物学応用

  • 実現技術の応用
  • 生物学的要素と統合システムの応用
  • 合成遺伝子
  • BioBrickパーツ
  • 対応製品の応用
  • DNA貯蔵用

第6章 合成生物学産業

  • 産業用バイオテクノロジーバリューチェーン
  • 産業構造力
  • 製品・技術のライフサイクル
  • DNAシークエンシング装置産業
  • 第3世代シークエンシング産業
  • オリゴヌクレオチド合成産業
  • 遺伝子合成産業

第7章 合成生物学市場

  • 産業成長促進要因
  • 合成生物学市場:エンドユーザー産業別
  • 合成生物学市場:製品タイプ別
  • 対応製品市場
  • 地域別市場

第8章 特許

  • イントロダクション
  • 基本的特許
  • 合成生物学産業の特許分析
  • ゲノム編集:CRISPR/CAS9 特許情勢

第9章 企業プロファイル

  • 20N LABS INC.
  • ABEONA THERAPEUTICS INC.
  • ACTIVE MOTIF
  • AGILIS BIOTHERAPEUTICS LLC
  • AGRIVIDA
  • ALGENUITY
  • AMBRX INC.
  • AMYRIS INC.
  • ARAKNITEK
  • ARZEDA CORP.
  • ASTRAZENECA PLC
  • ATG BIOSYNTHETICS GMBH
  • ATUM
  • AVIDBIOTICS CORP.
  • BASF AG
  • BAYER AG
  • BETA RENEWABLES
  • BIOAMBER INC.
  • BIO BASIC CANADA INC.
  • BIOMAX INFORMATICS AG
  • BIONEER CORP.
  • BIO S&T INC.
  • BLUEBIRD BIO
  • BLUE MARBLE BIOMATERIALS
  • BOLT THREADS
  • BRITISH PETROLEUM
  • BRISTOL-MYERS SQUIBB
  • CALYSTA INC.
  • CARGILL INC.
  • CARIBOU BIOSCIENCES INC.
  • CELL DESIGN LABS
  • CELLECTIS SA
  • CHAIN BIOTECHNOLOGY LTD
  • CIBUS INC.
  • CODEXIS INC.
  • DEMURIS LIMITED
  • DESKTOP GENETICS LTD.
  • DOW CHEMICAL COMPANY
  • E.I. DU PONT DE NEMOURS AND COMPANY
  • DYADIC INTERNATIONAL INC.
  • EDITAS MEDICINE INC.
  • ENBIOTIX INC.
  • ENEVOLV INC.
  • EPOCH LIFE SCIENCE INC.
  • EUROFINS MWG OPERON
  • EVOLVA SA
  • EVONETIX
  • EXXONMOBIL CORP.
  • GEN9 INC.
  • GENEMED SYNTHESIS INC.
  • GENE ORACLE INC.
  • GENEWORKS PTY. LTD.
  • GENOMATICA
  • GENSCRIPT
  • GEVO INC.
  • GINKGO BIOWORKS
  • GLAXOSMITHKLINE PLC
  • GLOBAL BIOENERGIES
  • GLYCOS BIOTECHNOLOGIES INC.
  • GOODYEAR TIRE & RUBBER CO.
  • GREEN BIOLOGICS LTD.
  • HELIX NANOTECHNOLOGIES INC.
  • ILLUMINA INC.
  • INDUSTRIAL MICROBES INC.
  • INGENZA LTD.
  • INOVIO PHARMACEUTICALS INC.
  • INTEGRATED DNA TECHNOLOGIES INC.
  • INTELLIA THERAPEUTICS
  • INTERNATIONAL BUSINESS MACHINES
  • INTREXON CORP.
  • JOULE UNLIMITED
  • JUNO THERAPEUTICS INC.
  • LABGENIUS LTD.
  • LANZATECH
  • LATTICE AUTOMATION INC.
  • LC SCIENCES
  • LYGOS INC.
  • MERCK & CO.
  • METABOLIX INC.
  • MICHELIN SA
  • MICROSOFT CORP.
  • MODULAR GENETICS INC.
  • MORPHOSYS AG
  • MYRIANT TECHNOLOGIES LLC
  • NEW ENGLAND BIOLABS
  • NOVARTIS PHARMA AG
  • NOVOZYMES A/S
  • OMEGA BIO-TEK INC.
  • ORAGENICS INC.
  • ORIGENE TECHNOLOGIES INC.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PFIZER INC.
  • PHYLOGICA LIMITED
  • PHYTOWELT GREEN TECHNOLOGIES GMBH
  • PRECISION BIOSCIENCES
  • PROKARIUM HOLDINGS LTD.
  • QTEROS INC.
  • RADIANT GENOMICS INC.
  • RENNOVIA INC.
  • ROOSTERBIO INC.
  • ROYAL DSM NV
  • SAMPLE6 TECHNOLOGIES
  • SANGAMO THERAPEUTICS INC.
  • SANOFI-AVENTIS
  • SCARAB GENOMICS LLC
  • SEA6 ENERGY PVT LTD.
  • SGI-DNA INC.
  • SHANGHAI GENERAY BIOTECH CO. LTD.
  • SHANGHAI SHINEGENE MOLECULAR BIO-TECHNOLOGIES INC.
  • SIGMA ALDRICH CORP.
  • SILICOLIFE LDA.
  • SOLIGENIX INC.
  • SPIBER INC.
  • SYNLOGIC
  • SYNPROMICS LTD.
  • SYNTHACE LTD.
  • SYNTHETIC BIOLOGICS INC.
  • SYNTHETIC GENOMICS INC.
  • SYNTHORX INC.
  • SYNVITROBIO INC.
  • TAXA BIO-ENGINEERING
  • TEEWINOT LIFE SCIENCES CORP.
  • TERRAVIA HOLDINGS INC.
  • TESELAGEN BIOTECHNOLOGY INC.
  • THERMO FISHER SCIENTIFIC INC.
  • TOUCHLIGHT GENETICS LTD
  • TRANSCRIPTIC INC.
  • TRITON ALGAE INNOVATIONS LTD.
  • TWIST BIOSCIENCE
  • VERDEZYNE INC.
  • ZIOPHARM ONCOLOGY INC.
  • ZYMERGEN

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO066D

Report Highlights

The global synthetic-biology market reached nearly $3.9 billion in 2016 and should reach $11.4 billion by 2021, growing at a compound annual growth rate (CAGR) of 24.0% through 2021.

Report Includes

  • An overview of the global markets for synthetic biology.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
  • Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
  • Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture
  • Analysis of the synthetic biology industry structure, competitors and intellectual property landscape
  • An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
  • Profiles of major players in the industry

Report Scope

The study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production systems), enabling technologies (DNA sequencing, DNA synthesis and assembly, genome editing, bioinformatics and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) that are already commercialized or are forecast to be commercialized within the next five years.

We analyze key synthetic-biology technologies and products to determine present and future market status, and forecasted growth from 2016 through 2021. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.

BCC Research examines the synthetic-biology industry by market segment, including the following segments: DNA sequencing; DNA synthesis; genome editing; synthetic-biology foundries; industrial biotechnology; pharmaceuticals; and agriculture. The role of key strategic alliances and acquisitions from 2014 through 2016 is discussed. Emerging markets including synthetic genes, synthetic-biology-enabled drugs and vaccines, genome-edited crops, chassis organisms, as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and more than 135 companies in these fields are highlighted.

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY PRODUCT TYPE, 2015-2021 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • SYNTHETIC-BIOLOGY TECHNOLOGIES COVERED IN THIS REPORT
    • TABLE 1: SCOPE
    • FIGURE 1 SYNTHETIC-BIOLOGY VALUE-ADDED CHAIN
  • WHAT IS SYNTHETIC BIOLOGY?
  • DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY
    • FIGURE 2: FROM THE NATURAL TO THE ARTIFICIAL
    • TABLE 2: SYNTHETIC-BIOLOGY PARADIGM
  • FORCES DRIVING SYNTHETIC-BIOLOGY MARKET GROWTH
    • TABLE 3: SYNTHETIC-BIOLOGY GROWTH: DRIVING FORCES
  • GLOBAL MARKETS FOR SYNTHETIC-BIOLOGY PRODUCTS
    • TABLE 4: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
  • LIFE-CYCLE STATUS OF PRODUCTS AND TECHNOLOGIES
    • TABLE 5: SYNTHETIC-BIOLOGY PRODUCTS AND TECHNOLOGY LIFE-CYCLE STAGE
  • SYNTHETIC-BIOLOGY INDUSTRY
    • TABLE 6: SYNTHETIC-BIOLOGY COMPETITORS BY MARKET FOCUS

CHAPTER 4 - SYNTHETIC-BIOLOGY TECHNOLOGIES

  • INTRODUCTION
    • SYNTHETIC BIOLOGY DEFINED
      • TABLE 7: SYNTHETIC BIOLOGY DEFINITIONS
    • HISTORY OF SYNTHETIC BIOLOGY
      • TABLE 8: SYNTHETIC-BIOLOGY HISTORY
    • PARADIGM SHIFT IN BIOLOGY
      • TABLE 9: PARADIGM SHIFT CAUSED BY SYNTHETIC BIOLOGY
      • TABLE 10: GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARED
      • FIGURE 3: SCALE OF SYNTHETIC BIOLOGY
    • SYNTHETIC-BIOLOGY TECHNOLOGY OVERVIEW
      • TABLE 11: SYNTHETIC-BIOLOGY APPLICATIONS BY TECHNOLOGY
    • ENABLING TECHNOLOGIES
      • TABLE 12: IMPORTANCE OF ENABLING TECHNOLOGIES
    • DNA-SYNTHESIS AND DNA-SEQUENCING COST TRENDS
      • TABLE 13: COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2015 ($)
      • TABLE 14: DNA-SYNTHESIS COSTS, 2006 AND 2016 ($/BP)
    • DNA-SYNTHESIS TECHNOLOGIES
      • FIGURE 4: SCHEMATIC OF DNA-SYNTHESIS TECHNOLOGIES
      • TABLE 15: COMPARISONS OF GENE-SYNTHESIS TECHNOLOGIES
      • PCR-Based Approaches
      • Solid-Phase-Based Approaches
    • MICROFLUIDIC TECHNOLOGIES
      • TABLE 16: IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY
      • DNA Microarrays
      • FIGURE 5: MICROARRAYS IN DNA SYNTHESIS
    • NEXT-GENERATION SEQUENCING TECHNOLOGIES
      • TABLE 17: NEXT-GENERATION SEQUENCING TECHNOLOGIES, BY COMPANY
    • GENOME-EDITING TOOLS
      • TABLE 18: COMPARISON OF GENENOME-EDITING PLATFORMS
      • TABLE 19: GENOME-EDITING TECHNOLOGIES: ADVANTAGES AND LIMITATIONS
    • GENE DRIVES
      • TABLE 20: POTENTIAL MARKET APPLICATIONS FOR GENE-DRIVE- MODIFIED ORGANISMS
    • BIOINFORMATICS TECHNOLOGIES
      • TABLE 21: SYNTHETIC-BIOLOGY BIOINFORMATICS TECHNOLOGIES
    • BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS TECHNOLOGIES
      • TABLE 22: NUCLEIC ACIDS, GENES AND GENOMES
    • SYNTHETIC DNA
      • TABLE 23: SYNTHETIC DNA
      • TABLE 24: SYNTHETIC GENES AS MOLECULAR-BIOLOGY TOOL
      • TABLE 25: SYNTHETIC GENES VERSUS PCR CLONING
    • BIOBRICK PARTS
      • TABLE 26: DNA CONSTRUCTS
      • FIGURE 6: ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC-BIOLOGY SYSTEMS
    • MINIMAL GENOMES AND CHASSIS ORGANISMS
      • TABLE 27: ATTRIBUTES OF A MINIMAL GENOME
      • Case Study: Minimal E. coli Genome
      • Role of Directed Evolution in Designing Biologic Parts
    • ENABLED TECHNOLOGIES
      • TABLE 28: ENABLED TECHNOLOGIES: KEY APPLICATION FIELDS
    • PATHWAY ENGINEERING
      • FIGURE 7: HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS
      • TABLE 29: METABOLIC ENGINEERING FOR ARTEMISINIC ACID
    • RESEARCH AND DEVELOPMENT APPLICATIONS
      • TABLE 30: RESEARCH AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC-BIOLOGY PRODUCTS
  • BIOFUELS TECHNOLOGIES
    • OVERVIEW
      • TABLE 31: ADVANCED BIOFUELS TYPES
    • FIRST- AND SECOND-GENERATION BIOFUEL TECHNOLOGIES
      • TABLE 32: FIRST--AND SECOND-GENERATION BIOFUELS COMPARED
    • CROP FEEDSTOCKS
      • TABLE 33: ENERGY BALANCE OF SELECTED FIRST-GENERATION BIOFUEL FEEDSTOCKS
    • CELLULOSIC FEEDSTOCKS
      • TABLE 34: APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS (%)
      • TABLE 35: SYNTHETIC-BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS INTO ETHANOL
    • ALGAE FEEDSTOCKS
      • TABLE 36: BIODIESEL YIELD OF SELECTED CROPS (GALLONS/ACRE/YEAR)
  • CARBON DIOXIDE FEEDSTOCKS
    • BIOFUEL END PRODUCTS
      • TABLE 37: EFFICIENCY OF VARIOUS FUELS (%)
      • Cellulosic Ethanol
      • FIGURE 8: CELLULOSIC ETHANOL PRODUCTION SCHEMATIC
      • Biodiesel
      • TABLE 38: IODINE NUMBER OF VARIOUS OILS
      • Other Biofuels
      • Role of Genetic Engineering and Synthetic Biology in Biofuels
      • TABLE 39: CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS
    • SYNTHETIC-BIOLOGY INITIATIVES
      • TABLE 40: SYNTHETIC-BIOLOGY INITIATIVES

CHAPTER 5 - SYNTHETIC-BIOLOGY APPLICATIONS

  • ENABLING TECHNOLOGIES APPLICATIONS
    • TABLE 41: SYNTHETIC-BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES
  • BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS APPLICATIONS
    • TABLE 42: BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM APPLICATIONS
  • SYNTHETIC GENES
    • TABLE 43: SYNTHETIC GENES NEAR-TERM APPLICATIONS
  • BIOBRICK PARTS
    • INTEGRATED SYSTEMS
      • TABLE 44: E. COLI AS A CHASSIS ORGANISM
  • ENABLED PRODUCTS APPLICATIONS
    • PHARMACEUTICALS
      • Drug Discovery and Development
        • TABLE 45: DRUG-DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC-BIOLOGY PRODUCTS
      • Genome-Edited Pharmaceuticals
        • TABLE 46: GENOME-EDITING NEAR-TERM CLINICAL APPLICATIONS
      • Immuno-Oncology
        • TABLE 47: CAR-T CELL ALLIANCES AND SYNTHETIC-BIOLOGY PLATFORMS
      • Other Pharmaceuticals Applications
        • TABLE 48: SYNTHETIC-BIOLOGY-ENABLED PHARMACEUTICAL APPLICATIONS
    • INDUSTRIAL BIOTECHNOLOGY APPLICATIONS
      • Biofuels
        • TABLE 49: SYNTHETIC-BIOLOGY-ENABLED BIOFUELS APPLICATIONS
        • TABLE 50: GROWTH STATUS OF SPECIALTY VERSUS DROP-IN BIOFUELS, 2000-2020
      • Chemicals
        • TABLE 51: SYNTHETIC-BIOLOGY-ENABLED CHEMICALS APPLICATIONS
    • AGRICULTURE AND ANIMALS APPLICATIONS
      • TABLE 52: SYNTHETIC-BIOLOGY-ENABLED AGRICULTURE AND ANIMALS APPLICATIONS
      • TABLE 53: REGULATORY STATUS OF GENOME-EDITIED CROPS
  • DNA STORAGE APPLICATIONS

CHAPTER 6 - SYNTHETIC-BIOLOGY INDUSTRY

  • INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN
    • FIGURE 9: INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY LEVERAGE POINTS
  • INDUSTRY STRUCTURAL FORCES
    • TABLE 54: SYNTHETIC-BIOLOGY INDUSTRY STRUCTURAL FORCES
  • PRODUCTS AND TECHNOLOGY LIFE CYCLE
    • TABLE 55: SYNTHETIC--BIOLOGY PRODUCTS AND TECHNOLOGY LIFE-CYCLE STAGE
  • DNA-SEQUENCING INSTRUMENT INDUSTRY
    • TABLE 56: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
  • THIRD-GENERATION SEQUENCING INDUSTRY
    • TABLE 57: THIRD-GENERATION SEQUENCING INDUSTRY
  • OLIGONUCLEOTIDE SYNTHESIS INDUSTRY
    • TABLE 58: GLOBAL MARKET SHARES OF OLIGONUCLEOTIDE SYNTHESIS INDUSTRY, BY COMPANY, 2016 ($ MILLIONS/%)
  • GENE-SYNTHESIS INDUSTRY
    • WORKFLOW
      • TABLE 59: GENE-SYNTHESIS WORKFLOW
    • COMPETITORS
      • TABLE 60: GLOBAL MARKET SHARES OF GENE-SYNTHESIS INDUSTRY, BY COMPANY, 2016 ($ MILLIONS/%)
      • TABLE 61: GENE-SYNTHESIS KEY COMPETITOR STRATEGIES
    • VALUE CHAIN
    • GENE-SYNTHESIS MARKET SEGMENTS
      • Standardized Segment
      • Value-Added Segment
        • TABLE 62: GENE-SYNTHESIS MARKET FACTORS OF DIFFERENTIATION
    • GENOME-EDITING TOOLS INDUSTRY
      • TABLE 63: GENOME-EDITING TOOLS INDUSTRY
    • SYNTHETIC-BIOLOGY FOUNDRIES INDUSTRY
      • TABLE 64: SYNTHETIC-BIOLOGY FOUNDRIES INDUSTRY
    • PHARMACEUTICALS INDUSTRY
      • TABLE 65: PHARMACEUTICALS INDUSTRY SYNTHETIC-BIOLOGY STRATEGIES
      • TABLE 66: MICROBIOME THERAPEUTICS INDUSTRY
    • AGRICULTURE INDUSTRY
      • TABLE 67: SYNTHETIC-BIOLOGY AGRICULTURE INDUSTRY
    • ACQUISITIONS AND STRATEGIC ALLIANCES
      • TABLE 68: SYNTHETIC-BIOLOGY INDUSTRY ACQUISITIONS, 2014-2016
      • TABLE 69: STRATEGIC ALLIANCES, 2014-2016

CHAPTER 7 - SYNTHETIC-BIOLOGY MARKETS

  • INDUSTRY GROWTH-DRIVING FORCES
    • TABLE 70: SYNTHETIC-BIOLOGY GROWTH-DRIVING FORCES
  • SYNTHETIC-BIOLOGY MARKETS BY END-USER INDUSTRY
    • RESEARCH MARKET
      • TABLE 71: GLOBAL VALUE OF RESEARCH MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • PHARMACEUTICALS MARKET
      • TABLE 72: GLOBAL VALUE OF PHARMACEUTIALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • CHEMICALS MARKET
      • TABLE 73: GLOBAL VALUE OF CHEMICALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • ENERGY MARKET
      • TABLE 74: GLOBAL VALUE OF ENERGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • AGRICULTURE MARKET
      • TABLE 75: GLOBAL VALUE OF AGRICULTURE MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • SYNTHETIC-BIOLOGY MARKET BY PRODUCT TYPE
      • TABLE 76: GLOBAL VALUE OF SYNTHETIC--BIOLOGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • ENABLING PRODUCTS MARKETS
      • TABLE 77: GLOBAL VALUE OF ENABLING PRODUCTS, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
      • TABLE 78: GLOBAL VALUE OF ENABLING PRODUCTS, BY END-USE INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • BIOLOGIC COMPONENTS MARKET
      • TABLE 79: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
      • Synthetic-Gene Standardized Market Segment
      • Synthetic-Gene Value-Added Market Segment
      • TABLE 80: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • INTEGRATED SYSTEMS MARKET
      • TABLE 81: GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
      • TABLE 82: GLOBAL VALUE OF INTEGRATED SYSTEMS, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
  • ENABLED PRODUCTS MARKET
    • SOURCES OF COMPETITIVE ADVANTAGE
      • TABLE 83: BIODIESEL FUEL PERFORMANCE COMPARISON
      • TABLE 84: ARTEMISININ DRUG PRODUCTION COMPARISON
      • TABLE 85: SWEETENER PRODUCT COMPARISON
      • TABLE 86: GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • PHARMACEUTICALS MARKET
      • TABLE 87: GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET, BY DRUG CLASS, THROUGH 2021 ($ MILLIONS)
    • CHEMICALS MARKET
      • TABLE 88: FACTORS FOR SYNTHETIC-BIOLOGY-BASED CHEMICAL PROCESSES
      • TABLE 89: GLOBAL VALUE OF ENABLED CHEMICALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • ENERGY MARKET
      • TABLE 90: ADVANCED BIOFUEL GROWTH FACTORS
      • TABLE 91: CRUDE OIL PRICES, 2011-2016
      • TABLE 92: STRATEGIC SHIFTS IN BIOFUELS
      • TABLE 93: GLOBAL VALUE OF THE ENERGY MARKET, BY FUEL TYPE, THROUGH 2021 ($ MILLIONS)
    • AGRICULTURE MARKET
      • TABLE 94: GLOBAL VALUE OF AGRICULTURE MARKET, BY END USE, THROUGH 2021 ($ MILLIONS)
      • Animals Market
        • TABLE 95: GLOBAL VALUE OF ANIMAL MARKET, BY APPLICATION, THROUGH 2021 ($ MILLIONS)
      • Pest-Control Market
        • TABLE 96: MOSQUITO-CONTROL METHODS
        • TABLE 97: AEDES AEGYPTI INITIAL MARKETS
      • Seeds Market
        • TABLE 98: GLOBAL VALUE OF SEED MARKETS, BY END-USE APPLICATION, THROUGH 2021 ($ MILLIONS)
        • TABLE 99: ADVANTAGES OF GENOME EDITING FOR CROP MODIFICATION
        • TABLE 100: GENOME-EDITED CROPS MARKET LANDSCAPE (MILLION TONNES)
        • TABLE 101: GENOME-EDITED CROPS COMMERCIALIZATION PATHWAY
  • REGIONAL MARKETS
    • SYNTHETIC-BIOLOGY PRODUCTS BY REGION
      • TABLE 102: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • ENABLING PRODUCTS MARKET BY REGION
      • TABLE 103: GLOBAL VALUE OF ENABLING PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • CORE PRODUCTS BY REGION
      • TABLE 104: GLOBAL VALUE OF CORE PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • ENABLED PRODUCTS BY REGION
      • TABLE 105: GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 106: BIOFUELS BLEND MANDATES IN KEY COUNTRIES (%)

CHAPTER 8 - PATENTS

  • INTRODUCTION
    • TABLE 107: SYNTHETIC-BIOLOGY PATENT SCOPE
  • FOUNDATIONAL PATENTS
    • TABLE 108: SYNTHETIC-BIOLOGY FOUNDATIONAL PATENTS
  • SYNTHETIC-BIOLOGY INDUSTRY PATENT ANALYSIS
    • TABLE 109: SYNTHETIC-BIOLOGY PATENT LANDSCAPE, BY COMPANY
    • TABLE 110: PATENT DESCRIPTION BY COMPANY
  • GENOME EDITING - CRISPR/CAS9 PATENT LANDSCAPE
    • TABLE 111: GENOME-EDITING PATENT LEADERS
    • TABLE 112: CRISPR-CAS9 IP LANDSCAPE

CHAPTER 9 - COMPANY PROFILES

  • 20N LABS INC.
  • ABEONA THERAPEUTICS INC.
  • ACTIVE MOTIF
  • AGILIS BIOTHERAPEUTICS LLC
  • AGRIVIDA
    • TABLE 113: AGRIVIDA TECHNICAL APPROACH
  • ALGENUITY
  • AMBRX INC.
  • AMYRIS INC.
  • ARAKNITEK
  • ARZEDA CORP.
  • ASTRAZENECA PLC
  • ATG BIOSYNTHETICS GMBH
  • ATUM
  • AVIDBIOTICS CORP.
  • BASF AG
  • BAYER AG
  • BETA RENEWABLES
  • BIOAMBER INC.
  • BIO BASIC CANADA INC.
  • BIOMAX INFORMATICS AG
  • BIONEER CORP.
  • BIO S&T INC.
  • BLUEBIRD BIO
  • BLUE MARBLE BIOMATERIALS
  • BOLT THREADS
  • BRITISH PETROLEUM
  • BRISTOL-MYERS SQUIBB
  • CALYSTA INC.
  • CARGILL INC.
  • CARIBOU BIOSCIENCES INC.
  • CELL DESIGN LABS
  • CELLECTIS SA
  • CHAIN BIOTECHNOLOGY LTD
  • CIBUS INC.
  • CODEXIS INC.
  • DEMURIS LIMITED
  • DESKTOP GENETICS LTD.
  • DOW CHEMICAL COMPANY
  • E.I. DU PONT DE NEMOURS AND COMPANY
  • DYADIC INTERNATIONAL INC.
  • EDITAS MEDICINE INC.
  • ENBIOTIX INC.
  • ENEVOLV INC.
  • EPOCH LIFE SCIENCE INC.
  • EUROFINS MWG OPERON
  • EVOLVA SA
    • TABLE 114: EVOLVA'S GENETIC CHEMISTRY PLATFORM
  • EVONETIX
  • EXXONMOBIL CORP.
  • GEN9 INC.
    • TABLE 115: LINEAR GENE-SYNTHESIS PRODUCTS
  • GENEMED SYNTHESIS INC.
  • GENE ORACLE INC.
  • GENEWORKS PTY. LTD.
  • GENOMATICA
  • GENSCRIPT
  • GEVO INC.
  • GINKGO BIOWORKS
    • TABLE 116: ENGINEERED-ORGANISM WORKFLOW
  • GLAXOSMITHKLINE PLC
  • GLOBAL BIOENERGIES
  • GLYCOS BIOTECHNOLOGIES INC.
  • GOODYEAR TIRE & RUBBER CO.
  • GREEN BIOLOGICS LTD.
  • HELIX NANOTECHNOLOGIES INC.
  • ILLUMINA INC.
    • TABLE 117: RECENT PLATFORMS INTRODUCED BY ILLUMINA
  • INDUSTRIAL MICROBES INC.
  • INGENZA LTD.
  • INOVIO PHARMACEUTICALS INC.
  • INTEGRATED DNA TECHNOLOGIES INC.
  • INTELLIA THERAPEUTICS
  • INTERNATIONAL BUSINESS MACHINES
  • INTREXON CORP.
  • JOULE UNLIMITED
  • JUNO THERAPEUTICS INC.
  • LABGENIUS LTD.
  • LANZATECH
  • LATTICE AUTOMATION INC.
  • LC SCIENCES
  • LYGOS INC.
  • MERCK & CO.
  • METABOLIX INC.
  • MICHELIN SA
  • MICROSOFT CORP.
  • MODULAR GENETICS INC.
  • MORPHOSYS AG
  • MYRIANT TECHNOLOGIES LLC
  • NEW ENGLAND BIOLABS
  • NOVARTIS PHARMA AG
  • NOVOZYMES A/S
  • OMEGA BIO-TEK INC.
  • ORAGENICS INC.
  • ORIGENE TECHNOLOGIES INC.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PFIZER INC.
  • PHYLOGICA LIMITED
  • PHYTOWELT GREEN TECHNOLOGIES GMBH
  • PRECISION BIOSCIENCES
  • PROKARIUM HOLDINGS LTD.
  • QTEROS INC.
  • RADIANT GENOMICS INC.
  • RENNOVIA INC.
  • ROOSTERBIO INC.
  • ROYAL DSM NV
  • SAMPLE6 TECHNOLOGIES
  • SANGAMO THERAPEUTICS INC.
  • SANOFI-AVENTIS
  • SCARAB GENOMICS LLC
  • SEA6 ENERGY PVT LTD.
  • SGI-DNA INC.
  • SHANGHAI GENERAY BIOTECH CO. LTD.
  • SHANGHAI SHINEGENE MOLECULAR BIO-TECHNOLOGIES INC.
  • SIGMA ALDRICH CORP.
  • SILICOLIFE LDA.
  • SOLIGENIX INC.
  • SPIBER INC.
  • SYNLOGIC
  • SYNPROMICS LTD.
  • SYNTHACE LTD.
  • SYNTHETIC BIOLOGICS INC.
  • SYNTHETIC GENOMICS INC.
  • SYNTHORX INC.
  • SYNVITROBIO INC.
  • TAXA BIO-ENGINEERING
  • TEEWINOT LIFE SCIENCES CORP.
  • TERRAVIA HOLDINGS INC.
  • TESELAGEN BIOTECHNOLOGY INC.
  • THERMO FISHER SCIENTIFIC INC.
  • TOUCHLIGHT GENETICS LTD
  • TRANSCRIPTIC INC.
  • TRITON ALGAE INNOVATIONS LTD.
  • TWIST BIOSCIENCE
  • VERDEZYNE INC.
  • ZIOPHARM ONCOLOGY INC.
  • ZYMERGEN

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: SCOPE
    • TABLE 2: SYNTHETIC-BIOLOGY PARADIGM
    • TABLE 3: SYNTHETIC-BIOLOGY GROWTH: DRIVING FORCES
    • TABLE 4: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 5: SYNTHETIC-BIOLOGY PRODUCTS AND TECHNOLOGY LIFE-CYCLE STAGE
    • TABLE 6: SYNTHETIC-BIOLOGY COMPETITORS BY MARKET FOCUS
    • TABLE 7: SYNTHETIC BIOLOGY DEFINITIONS
    • TABLE 8: SYNTHETIC-BIOLOGY HISTORY
    • TABLE 9: PARADIGM SHIFT CAUSED BY SYNTHETIC BIOLOGY
    • TABLE 10: GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARED
    • TABLE 11: SYNTHETIC-BIOLOGY APPLICATIONS BY TECHNOLOGY
    • TABLE 12: IMPORTANCE OF ENABLING TECHNOLOGIES
    • TABLE 13: COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2015 ($)
    • TABLE 14: DNA-SYNTHESIS COSTS, 2006 AND 2016 ($/BP)
    • TABLE 15: COMPARISONS OF GENE-SYNTHESIS TECHNOLOGIES
    • TABLE 16: IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY
    • TABLE 17: NEXT-GENERATION SEQUENCING TECHNOLOGIES, BY COMPANY
    • TABLE 18: COMPARISON OF GENENOME-EDITING PLATFORMS
    • TABLE 19: GENOME-EDITING TECHNOLOGIES: ADVANTAGES AND LIMITATIONS
    • TABLE 20: POTENTIAL MARKET APPLICATIONS FOR GENE-DRIVE- MODIFIED ORGANISMS
    • TABLE 21: SYNTHETIC-BIOLOGY BIOINFORMATICS TECHNOLOGIES
    • TABLE 22: NUCLEIC ACIDS, GENES AND GENOMES
    • TABLE 23: SYNTHETIC DNA
    • TABLE 24: SYNTHETIC GENES AS MOLECULAR-BIOLOGY TOOL
    • TABLE 25: SYNTHETIC GENES VERSUS PCR CLONING
    • TABLE 26: DNA CONSTRUCTS
    • TABLE 27: ATTRIBUTES OF A MINIMAL GENOME
    • TABLE 28: ENABLED TECHNOLOGIES: KEY APPLICATION FIELDS
    • TABLE 29: METABOLIC ENGINEERING FOR ARTEMISINIC ACID
    • TABLE 30: RESEARCH AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC-BIOLOGY PRODUCTS
    • TABLE 31: ADVANCED BIOFUELS TYPES
    • TABLE 32: FIRST--AND SECOND-GENERATION BIOFUELS COMPARED
    • TABLE 33: ENERGY BALANCE OF SELECTED FIRST-GENERATION BIOFUEL FEEDSTOCKS
    • TABLE 34: APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS (%)
    • TABLE 35: SYNTHETIC-BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS INTO ETHANOL
    • TABLE 36: BIODIESEL YIELD OF SELECTED CROPS (GALLONS/ACRE/YEAR)
    • TABLE 37: EFFICIENCY OF VARIOUS FUELS (%)
    • TABLE 38: IODINE NUMBER OF VARIOUS OILS
    • TABLE 39: CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS
    • TABLE 40: SYNTHETIC-BIOLOGY INITIATIVES
    • TABLE 41: SYNTHETIC-BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES
    • TABLE 42: BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM APPLICATIONS
    • TABLE 43: SYNTHETIC GENES NEAR-TERM APPLICATIONS
    • TABLE 44: E. COLI AS A CHASSIS ORGANISM
    • TABLE 45: DRUG-DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC-BIOLOGY PRODUCTS
    • TABLE 46: GENOME-EDITING NEAR-TERM CLINICAL APPLICATIONS
    • TABLE 47: CAR-T CELL ALLIANCES AND SYNTHETIC-BIOLOGY PLATFORMS
    • TABLE 48: SYNTHETIC-BIOLOGY-ENABLED PHARMACEUTICAL APPLICATIONS
    • TABLE 49: SYNTHETIC-BIOLOGY-ENABLED BIOFUELS APPLICATIONS
    • TABLE 50: GROWTH STATUS OF SPECIALTY VERSUS DROP-IN BIOFUELS, 2000-2020
    • TABLE 51: SYNTHETIC-BIOLOGY-ENABLED CHEMICALS APPLICATIONS
    • TABLE 52: SYNTHETIC-BIOLOGY-ENABLED AGRICULTURE AND ANIMALS APPLICATIONS
    • TABLE 53: REGULATORY STATUS OF GENOME-EDITIED CROPS
    • TABLE 54: SYNTHETIC-BIOLOGY INDUSTRY STRUCTURAL FORCES
    • TABLE 55: SYNTHETIC--BIOLOGY PRODUCTS AND TECHNOLOGY LIFE-CYCLE STAGE
    • TABLE 56: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
    • TABLE 57: THIRD-GENERATION SEQUENCING INDUSTRY
    • TABLE 58: GLOBAL MARKET SHARES OF OLIGONUCLEOTIDE SYNTHESIS INDUSTRY, BY COMPANY, 2016 ($ MILLIONS/%)
    • TABLE 59: GENE-SYNTHESIS WORKFLOW
    • TABLE 60: GLOBAL MARKET SHARES OF GENE-SYNTHESIS INDUSTRY, BY COMPANY, 2016 ($ MILLIONS/%)
    • TABLE 61: GENE-SYNTHESIS KEY COMPETITOR STRATEGIES
    • TABLE 62: GENE-SYNTHESIS MARKET FACTORS OF DIFFERENTIATION
    • TABLE 63: GENOME-EDITING TOOLS INDUSTRY
    • TABLE 64: SYNTHETIC-BIOLOGY FOUNDRIES INDUSTRY
    • TABLE 65: PHARMACEUTICALS INDUSTRY SYNTHETIC-BIOLOGY STRATEGIES
    • TABLE 66: MICROBIOME THERAPEUTICS INDUSTRY
    • TABLE 67: SYNTHETIC-BIOLOGY AGRICULTURE INDUSTRY
    • TABLE 68: SYNTHETIC-BIOLOGY INDUSTRY ACQUISITIONS, 2014-2016
    • TABLE 69: STRATEGIC ALLIANCES, 2014-2016
    • TABLE 70: SYNTHETIC-BIOLOGY GROWTH-DRIVING FORCES
    • TABLE 71: GLOBAL VALUE OF RESEARCH MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 72: GLOBAL VALUE OF PHARMACEUTIALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 73: GLOBAL VALUE OF CHEMICALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 74: GLOBAL VALUE OF ENERGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 75: GLOBAL VALUE OF AGRICULTURE MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 76: GLOBAL VALUE OF SYNTHETIC--BIOLOGY MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 77: GLOBAL VALUE OF ENABLING PRODUCTS, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 78: GLOBAL VALUE OF ENABLING PRODUCTS, BY END-USE INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 79: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 80: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 81: GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 82: GLOBAL VALUE OF INTEGRATED SYSTEMS, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 83: BIODIESEL FUEL PERFORMANCE COMPARISON
    • TABLE 84: ARTEMISININ DRUG PRODUCTION COMPARISON
    • TABLE 85: SWEETENER PRODUCT COMPARISON
    • TABLE 86: GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY END-USER INDUSTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 87: GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET, BY DRUG CLASS, THROUGH 2021 ($ MILLIONS)
    • TABLE 88: FACTORS FOR SYNTHETIC-BIOLOGY-BASED CHEMICAL PROCESSES
    • TABLE 89: GLOBAL VALUE OF ENABLED CHEMICALS MARKET, BY PRODUCT TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 90: ADVANCED BIOFUEL GROWTH FACTORS
    • TABLE 91: CRUDE OIL PRICES, 2011-2016
    • TABLE 92: STRATEGIC SHIFTS IN BIOFUELS
    • TABLE 93: GLOBAL VALUE OF THE ENERGY MARKET, BY FUEL TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 94: GLOBAL VALUE OF AGRICULTURE MARKET, BY END USE, THROUGH 2021 ($ MILLIONS)
    • TABLE 95: GLOBAL VALUE OF ANIMAL MARKET, BY APPLICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 96: MOSQUITO-CONTROL METHODS
    • TABLE 97: AEDES AEGYPTI INITIAL MARKETS
    • TABLE 98: GLOBAL VALUE OF SEED MARKETS, BY END-USE APPLICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 99: ADVANTAGES OF GENOME EDITING FOR CROP MODIFICATION
    • TABLE 100: GENOME-EDITED CROPS MARKET LANDSCAPE (MILLION TONNES)
    • TABLE 101: GENOME-EDITED CROPS COMMERCIALIZATION PATHWAY
    • TABLE 102: GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 103: GLOBAL VALUE OF ENABLING PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 104: GLOBAL VALUE OF CORE PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 105: GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 106: BIOFUELS BLEND MANDATES IN KEY COUNTRIES (%)
    • TABLE 107: SYNTHETIC-BIOLOGY PATENT SCOPE
    • TABLE 108: SYNTHETIC-BIOLOGY FOUNDATIONAL PATENTS
    • TABLE 109: SYNTHETIC-BIOLOGY PATENT LANDSCAPE, BY COMPANY
    • TABLE 110: PATENT DESCRIPTION BY COMPANY
    • TABLE 111: GENOME-EDITING PATENT LEADERS
    • TABLE 112: CRISPR-CAS9 IP LANDSCAPE
    • TABLE 113: AGRIVIDA TECHNICAL APPROACH
    • TABLE 114: EVOLVA'S GENETIC CHEMISTRY PLATFORM
    • TABLE 115: LINEAR GENE-SYNTHESIS PRODUCTS
    • TABLE 116: ENGINEERED-ORGANISM WORKFLOW
    • TABLE 117: RECENT PLATFORMS INTRODUCED BY ILLUMINA

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC-BIOLOGY MARKET, BY PRODUCT TYPE, 2015-2021 ($ MILLIONS)
  • FIGURE 1: SYNTHETIC-BIOLOGY VALUE-ADDED CHAIN
  • FIGURE 2: FROM THE NATURAL TO THE ARTIFICIAL
  • FIGURE 3: SCALE OF SYNTHETIC BIOLOGY
  • FIGURE 4: SCHEMATIC OF DNA-SYNTHESIS TECHNOLOGIES
  • FIGURE 5: MICROARRAYS IN DNA SYNTHESIS
  • FIGURE 6: ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC-BIOLOGY SYSTEMS
  • FIGURE 7: HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS
  • FIGURE 8: CELLULOSIC ETHANOL PRODUCTION SCHEMATIC
  • FIGURE 9: INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY LEVERAGE POINTS
Back to Top